| Literature DB >> 26369701 |
Erika Vacchelli1,2,3,4,5, Michaela Semeraro1,6,7, David P Enot1,2,3,8, Kariman Chaba1,2,3,4, Vichnou Poirier Colame1,6,7, Peggy Dartigues9, Aurelie Perier1,6,7, Irene Villa10, Sylvie Rusakiewicz1,6,7, Caroline Gronnier11,12, Diane Goéré1,13, Christophe Mariette11,12, Laurence Zitvogel1,6,7,14, Guido Kroemer1,2,3,4,5,8,15.
Abstract
Ever accumulating evidence indicates that the long-term effects of radiotherapy and chemotherapy largely depend on the induction (or restoration) of an anticancer immune response. Here, we investigated this paradigm in the context of esophageal carcinomas treated by neo-adjuvant radiochemotherapy, in a cohort encompassing 196 patients. We found that the density of the FOXP3+ regulatory T cell (Treg) infiltrate present in the residual tumor (or its scar) correlated with the pathological response (the less Tregs the more pronounced was the histological response) and predicted cancer-specific survival. In contrast, there was no significant clinical impact of the frequency of CD8+ cytotoxic T cells. At difference with breast or colorectal cancer, a loss-of-function allele of toll like receptor 4 (TLR4) improved cancer-specific survival of patients with esophageal cancer. While a loss-of-function allele of purinergic receptor P2X, ligand-gated ion channel, 7 (P2RX7) failed to affect cancer-specific survival, its presence did correlate with an increase in Treg infiltration. Altogether, these results corroborate the notion that the immunosurveillance seals the fate of patients with esophageal carcinomas treated with conventional radiochemotherapy.Entities:
Keywords: ATG16L1; apoptosis; autophagy; immunogenic cell death; pattern recognition receptor
Mesh:
Substances:
Year: 2015 PMID: 26369701 PMCID: PMC4673233 DOI: 10.18632/oncotarget.4428
Source DB: PubMed Journal: Oncotarget ISSN: 1949-2553
Clinical and histopathology characteristics of the 196 esophageal cancer patients
| Cohort parameters | Variable | n (%) |
|---|---|---|
| Clinical parameters | ||
| Gender | ||
| M | 177 (90.3) | |
| F | 19 (9.7) | |
| Smokers | ||
| No | 19 (9.7) | |
| Yes | 167 (85.2) | |
| Missing | 10 (5.1) | |
| Alcoholics | ||
| No | 21 (10.7) | |
| Yes | 125 (63.8) | |
| Missing | 50 (25.5) | |
| Denutrition | ||
| No | 136 (69.4) | |
| Yes | 60 (30.6) | |
| Tumor related parameters | ||
| T of TNM | ||
| T0 | 64 (32.7) | |
| T1 | 22 (11.2) | |
| T2 | 23 (11.7) | |
| T3 | 63 (32.1) | |
| T4 | 18 (9.2) | |
| Missing | 6 (3.1) | |
| N of TNM | ||
| N0 | 116 (59.2) | |
| N1 | 54 (27.6) | |
| N2 | 20 (10.2) | |
| N3 | 6 (3.1) | |
| M of TNM | ||
| M0 | 186 (94.9) | |
| M1 | 9 (4.6) | |
| Missing | 1 (0.5) | |
| Metastasis localization | ||
| No | 186 (94.9) | |
| Liver | 3 (1.6) | |
| Lung | 3 (1.5) | |
| Stomac | 3 (1.5) | |
| Missing | 1 (0.5) | |
| Site | ||
| Neck | 5 (2.6) | |
| Cervical | 10 (5.1) | |
| Thoracical | 38 (19.4) | |
| Mid Third | 105 (53.6) | |
| Lower Third | 38 (19.4) | |
| Histological differentiation | ||
| High | 108 (55.1) | |
| Mid | 36 (18.4) | |
| Low | 11 (5.6) | |
| Missing | 41 (20.9) | |
| Response to treatment | ||
| Complete response | 55 (28.1) | |
| Partial response | 102 (52.0) | |
| Stable disease | 30 (15.3) | |
| Progressive disease | 6 (3.1) | |
| Missing | 3 (1.5) | |
| Mandard classification (TRG) | ||
| Grade 1 | 64 (33) | |
| Grade 2 | 23 (12) | |
| Grade 3 | 33 (17) | |
| Grade 4 | 56 (28) | |
| Grade 5 | 20 (10) | |
Abbreviations: F, female; M, male; n, number; TNM, Tumor-Node-Mestastais; TRG, tumor regression grade.
Figure 1Impact of TLR4 and P2RX7 loss-of-function alleles on cancer-specific survival in esophageal cancer
A. Kaplan-Meier of the cancer-specific survival estimated in a cohort of esophageal cancer patients (n = 196) treated with neo-adjuvant cisplatin-based radiochemotherapy and bearing TLR4 rs4986780 with AA (wild type, Asp299) or AG (heterozygous, Asp299Gly) genotype. B. Kaplan-Meier of the cancer-specific survival estimated in a cohort of esophageal cancer patients (n = 194) treated with neo-adjuvant radiochemotherapy and bearing P2RX7 rs3751143 with AA (wild type, Glu496) or AC (heterozygous, Glu496Ala) + CC (mutated homozygous, Ala496Ala) genotypes. Statistical significance was determined by likelihood ratio test (LRT).
Figure 2Enumeration of CD8+ infiltrating lymphocytes in esophageal cancer
A. Representative picture of immunohistochemical staining of primary paraffin embedded esophageal carcinoma using CD8 specific antibody. Positive cells are stained brown. The exact number of CD8+ lymphocytes was evaluated in the tumor site and in the surrounding healthy or cicatricial tissue. B. Plot of the log-rank statistics at all possible values of CD8+ lymphocytes infiltration used to establish a cut-off that optimally separate the cohort into 2 prognostic groups. p values are simulated by Monte Carlo sampling (B=1999) and approximated log-rank statistics corresponding to the p < 0.05, p < 0.01 and p < 0.001 significance thresholds drawn as dotted horizontal lines. C., D. Kaplan-Meier of the cancer-specific survival (n = 174) according to the median C. or terciles D. of CD8+ infiltrating lymphocytes at the time of surgery.
Figure 3Enumeration of FOXP3+ T regulatory infiltrating lymphocytes in esophageal cancer
A. Representative picture of immunohistochemical staining of primary paraffin embedded esophageal carcinoma using FOXP3 specific antibody. Positive cells are stained brown. The exact number of FOXP3+ lymphocytes was evaluated in the tumor site and in the surrounding healthy or cicatricial tissue. B. Plot of the log-rank statistics at all possible values of FOXP3+ lymphocytes infiltration used to establish a cut-off that optimally separate the cohort into 2 prognostic groups. p values are simulated by Monte Carlo sampling (B=1999) and approximated log-rank statistics corresponding to the p < 0.05, p < 0.01 and p < 0.001 significance thresholds drawn as dotted horizontal lines. C.,D. Kaplan-Meier of the cancer specific-survival (n = 195) according to the median C. or terciles D. of FOXP3+ infiltrating lymphocytes at the time of surgery.
Figure 4Distribution of FOXP3+ T regulatory infiltrating lymphocytes according to clinical parameters and treatment response
Enumeration of FOXP3+ cells according to tumor staging at the time of surgery A., lymph nodes involvement B., presence of metastasis C., tumor regression grading (TRG) D.. *** p < 0.001 (one way ANOVA test).
Figure 5Correlation of FOXP3+ T regulatory infiltrating lymphocytes and comorbidities
FOXP3+ T regulatory lymphocytes infiltrating tumor or cicatritial tissue were associated with smoking status A. or alcohol consumption B. in esophageal cancer patients. ns, non significant, *** p < 0.001 (unpaired Student's t test).
Figure 6Single nucleotide polymorphisms (SNPs) association with infiltrating FOXP3+ lymphocytes
Distribution of FOXP3+ lymphocytes levels across the genoptypes of TLR4 (rs4986790) A. and P2RX7 (rs3751143) B.. Each dot represents one patient. ** p < 0.01 (unpaired t-test).